Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Ontology highlight
ABSTRACT: This is a multicenter observational study aimed to describe the efficacy and safety of regorafenib plus programmed cell death-1 (PD-1) inhibitors in Chinese patients with advanced colorectal cancer in routine clinical practice. The primary end point is overall survival. The secondary endpoints include progression-free survival, objective response rate, disease control rate and the incidence of treatment-related adverse events.
DISEASE(S): Advanced Colorectal Carcinoma,Colorectal Neoplasms
PROVIDER: 2368689 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA